DK1509232T3 - Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom - Google Patents

Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Info

Publication number
DK1509232T3
DK1509232T3 DK03724895T DK03724895T DK1509232T3 DK 1509232 T3 DK1509232 T3 DK 1509232T3 DK 03724895 T DK03724895 T DK 03724895T DK 03724895 T DK03724895 T DK 03724895T DK 1509232 T3 DK1509232 T3 DK 1509232T3
Authority
DK
Denmark
Prior art keywords
disease
combination
acetylcholine esterase
nmda antagonist
treat alzheimer
Prior art date
Application number
DK03724895T
Other languages
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1509232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1509232T3 publication Critical patent/DK1509232T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03724895T 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom DK1509232T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1509232T3 true DK1509232T3 (da) 2009-02-23

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03724895T DK1509232T3 (da) 2002-05-31 2003-05-22 Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom

Country Status (17)

Country Link
EP (1) EP1509232B1 (da)
JP (1) JP2005528431A (da)
AT (1) ATE414519T1 (da)
AU (1) AU2003227516B2 (da)
BR (1) BR0311375A (da)
CY (1) CY1108725T1 (da)
DE (1) DE60324788D1 (da)
DK (1) DK1509232T3 (da)
ES (1) ES2314200T3 (da)
IL (1) IL165255A0 (da)
MX (1) MXPA04011762A (da)
NO (1) NO332754B1 (da)
NZ (1) NZ536603A (da)
PL (1) PL373903A1 (da)
PT (1) PT1509232E (da)
SI (1) SI1509232T1 (da)
WO (1) WO2003101458A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
PL1703902T3 (pl) * 2004-01-05 2011-04-29 Merz Pharma Gmbh & Co Kgaa Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
WO2005070429A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
WO2006058059A2 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
AU2006241771B2 (en) 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2590696B1 (en) 2010-07-05 2017-03-08 Gambro Lundia AB An ambulatory ultrafiltration device, related methods and a computer program product
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
NZ747797A (en) * 2016-05-18 2020-07-31 Suven Life Sciences Ltd Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP4238555A3 (en) 2019-05-31 2023-09-20 Tecnimede, Sociedade Técnico-Medicinal, SA Immediate release fixed-dose combination of memantine and donepezil

Also Published As

Publication number Publication date
ES2314200T3 (es) 2009-03-16
EP1509232A1 (en) 2005-03-02
ATE414519T1 (de) 2008-12-15
SI1509232T1 (sl) 2009-04-30
WO2003101458A1 (en) 2003-12-11
NO332754B1 (no) 2013-01-07
NZ536603A (en) 2007-06-29
DE60324788D1 (de) 2009-01-02
MXPA04011762A (es) 2005-03-31
NO20045434L (no) 2004-12-13
AU2003227516B2 (en) 2008-03-20
EP1509232B1 (en) 2008-11-19
CY1108725T1 (el) 2014-04-09
BR0311375A (pt) 2005-03-15
AU2003227516A1 (en) 2003-12-19
IL165255A0 (en) 2005-12-18
JP2005528431A (ja) 2005-09-22
PL373903A1 (en) 2005-09-19
PT1509232E (pt) 2009-01-07

Similar Documents

Publication Publication Date Title
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO996578L (no) Urokinase-inhibitorer
NO20040211L (no) Kombinasjon av en aldosteronreseptor for antagonist og en HMB COA-reduktaseinhibitor
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
ATE443044T1 (de) Tace inhibitoren
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom